APELLIS PHARMACEUTICALS ($APLS) posted quarterly earnings results on Thursday, July 31st. The company reported earnings of -$0.33 per share, beating estimates of -$0.49 by $0.16. The company also reported revenue of $178,490,000, missing estimates of $192,287,034 by $-13,797,034.
You can see Quiver Quantitative's $APLS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
APELLIS PHARMACEUTICALS Insider Trading Activity
APELLIS PHARMACEUTICALS insiders have traded $APLS stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $APLS stock by insiders over the last 6 months:
- CEDRIC FRANCOIS (Chief Executive Officer) has made 0 purchases and 3 sales selling 159,090 shares for an estimated $3,211,826.
- DAVID O. WATSON (General Counsel) has made 0 purchases and 3 sales selling 15,569 shares for an estimated $331,389.
- MARK JEFFREY DELONG (Chief Business & Strat Officer) sold 363 shares for an estimated $10,359
- JAMES GEORGE CHOPAS (VP/Chief Accounting Officer) sold 183 shares for an estimated $4,542
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
APELLIS PHARMACEUTICALS Hedge Fund Activity
We have seen 139 institutional investors add shares of APELLIS PHARMACEUTICALS stock to their portfolio, and 125 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OCTAGON CAPITAL ADVISORS LP removed 3,006,980 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $65,762,652
- AQR CAPITAL MANAGEMENT LLC added 2,220,977 shares (+119.6%) to their portfolio in Q1 2025, for an estimated $48,572,766
- BANK OF AMERICA CORP /DE/ added 1,451,223 shares (+86.4%) to their portfolio in Q1 2025, for an estimated $31,738,247
- ORBIMED ADVISORS LLC added 1,432,300 shares (+inf%) to their portfolio in Q1 2025, for an estimated $31,324,401
- CIBC WORLD MARKETS CORP removed 1,285,300 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $28,109,511
- POINT72 ASSET MANAGEMENT, L.P. removed 1,267,958 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $27,730,241
- CANADA PENSION PLAN INVESTMENT BOARD added 1,013,500 shares (+2879.3%) to their portfolio in Q1 2025, for an estimated $22,165,245
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
APELLIS PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $APLS in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 07/29/2025
- Baird issued a "Outperform" rating on 07/18/2025
- Raymond James issued a "Outperform" rating on 05/09/2025
- Needham issued a "Buy" rating on 05/07/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/29/2025
- JP Morgan issued a "Overweight" rating on 03/04/2025
- HC Wainwright & Co. issued a "Buy" rating on 03/03/2025
To track analyst ratings and price targets for APELLIS PHARMACEUTICALS, check out Quiver Quantitative's $APLS forecast page.
APELLIS PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $APLS recently. We have seen 15 analysts offer price targets for $APLS in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $46.0 on 07/29/2025
- Colleen Kusy from Baird set a target price of $50.0 on 07/18/2025
- Tazeen Ahmad from B of A Securities set a target price of $24.0 on 07/16/2025
- Judah Frommer from Morgan Stanley set a target price of $26.0 on 07/02/2025
- Derek Archila from Wells Fargo set a target price of $29.0 on 06/02/2025
- Graig Suvannavejh from Mizuho set a target price of $20.0 on 05/14/2025
- Ryan Deschner from Raymond James set a target price of $52.0 on 05/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
